CannabisNewsBreaks

MondayFeb 26, 2018 10:15 am

CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Appoints Director of International Operations

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced its appointment of Dr. Maher Khaled to the position of director of international operations. Khaled bolsters the PreveCeutical team with more than a decade of experience in commercializing therapeutic and diagnostic technologies, most recently at UniQuest Pty Ltd. Moving forward, he will be involved in overseeing PreveCeutical’s development of therapeutic technologies, as well as managing the company’s ongoing operations in Australia, reviewing acquisition and licensing opportunities and leading commercialization efforts for its growing IP portfolio. “We are delighted to have Dr. Khaled as part of…

Continue Reading

MondayFeb 26, 2018 9:29 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Global Licensing Agreement with Neutrisci International Inc. (TSX-V: NU) (OTCQB: NRXCF)

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said it has entered an agreement with NeutriSci International Inc. (TSX-V: NU) (OTCQB: NRXCF) resulting in NeutriSci now having 100% ownership of Ambarii Trade Corporation. Lexaria has also granted to NeutriSci an Intellectual Property License and Supply Agreement for the manufacturing and sale of CBD based products. Per the License Agreement, NeutriSci will remain focused on the development and sales of its existing and pipeline products that include Lexaria's technology for enhancing palatability and bioavailability of beneficial non-psychoactive cannabinoids. Lexaria will receive continuing royalty revenues from the sales generated by these products.…

Continue Reading

FridayFeb 23, 2018 10:29 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Signs Agreement to Acquire Sechelt Organic Marijuana Corp.

Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), a pharmaceutical and IP development firm, this morning announced that it has signed an agreement with 906474 ALBERTA LTD (“the vender”), to purchase 100% ownership of Sechelt Organic Marijuana Corp (“SOM”). Under the agreement, Veritas Pharma will purchase all outstanding shares of SOM at a price of $800,000, subject to provisions of the closing agreement. The agreement requires the vender and SOM to give Veritas Pharma unlimited access to the operations, assets, properties, and records of SOM to help it familiarize with the operations, assets, records, properties and other matters on continuous…

Continue Reading

FridayFeb 23, 2018 9:28 am

CannabisNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) Enters LOI Detailing Proposed Acquisition of Agro-Biotech Inc.

Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) yesterday announced its entry into a non-binding letter of intent pursuant to which it proposes to acquire Agro-Biotech Inc., a Health Canada ACMPR licensed producer located in Saint-Eustache, Quebec. Upon completion of the proposed transaction, which is expected to occur by April 15, 2018, Agro-Biotech will continue to operate on a standalone basis. “With this acquisition, we are well positioned to enter the Québec cannabis market and attract experienced scientists to our organization. Pivot will seek to expand its footprint in the province beginning immediately following financing activities which are…

Continue Reading

ThursdayFeb 22, 2018 2:55 pm

CannabisNewsBreaks – Teewinot Life Sciences Produces Cannabinoids through Patent-protected CANNSYNTHESIS Technology

Cannabinoid-based pharmaceuticals company Teewinot Life Sciencess employs its patent-protected CANNSYNTHESIS® technology to biosynthesize cannabinoids for the large-scale manufacture of pharmaceutically pure cannabinoids. An article discussing the company’s technology reads: “Apart from THC and CBD, many of the 111 or so cannabinoids found in the cannabis plant are produced in minute quantities. Production by extraction is thus prohibitively costly, meaning that most cannabinoids have not been available for research and therapeutic applications. The CANNSYNTHESIS® platform has changed that paradigm, however, since it allows for the efficient production of cannabinoids in kilogram quantities. Teewinot’s CANNSYNTHESIS® has taken the production of cannabinoids from…

Continue Reading

ThursdayFeb 22, 2018 10:26 am

CannabisNewsBreaks – Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) and Blox Labs Inc. (CSE: BLOX) (OTC: BLLXF) (Frankfurt: BR1B) Provide Update on cannaBLOX Development

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) together with Blox Labs Inc. (CSE: BLOX) (OTC: BLLXF) (Frankfurt: BR1B) provided an update this morning regarding the initial phase 1 development of "cannaBLOX". The two companies have partnered together to develop the blockchain-based smart contract supply chain management platform for the legalized cannabis industry. Among other highlights, the update states that BLOX has completed the initial framework and analysis required for cannaBLOX Whitepaper and is working towards completion. Additionally, a satellite development team that is specialized in blockchain and decentralized application technologies has been formed in Eastern Europe. Liberty…

Continue Reading

WednesdayFeb 21, 2018 9:28 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Issues Corporate Update Detailing Q1 2018 Milestones

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning issued an official corporate update on its achievements, related scientific activities and growth strategies for the first quarter of fiscal 2018. Highlights include the company’s ongoing search for prospective office and research lab space on the campus of the University of British Columbia, its subsidiary’s progress toward the commencement of human trials in Puerto Rico studying lead cannabis strain CTL-X for pain management, its reception of a Health Canada dealer license through subsidiary Cannevert Therapeutics Ltd. (“CTL”) and CTL’s initiation of a cancer…

Continue Reading

TuesdayFeb 20, 2018 9:22 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Preparing for Planned Q1 Takeover of Cannevert Therapeutics

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), alongside research arm Cannevert Therapeutics Ltd., this morning announced that it is in the process of obtaining a fairness opinion from Davidson & Company LLP of Vancouver, Canada, regarding Veritas’ planned acquisition of the remaining 20 percent of Cannevert in the first quarter of 2018. Per the update, a fairness opinion is defined as “any written communication containing a conclusion as to the fairness of a proposed transaction to security holders, from a financial point of view.” Davidson & Company is expected to perform this…

Continue Reading

FridayFeb 16, 2018 9:24 am

CannabisNewsBreaks – Why Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) is “One to Watch”

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) is engaged in acquiring and developing a strategic portfolio of companies that also believe in the substantial potential of the industrial hemp plant. An article discussing the company reads: “The company’s mission is to build a strategic portfolio of hemp-based companies that operate synergistically to consistently deliver a solid ROI to its shareholders. Global Hemp Group has established the concept of Hemp Agro-Industrial Zone (HAIZ) (https://globalhempgroup.com/hempagro/) in order to build cooperative mechanisms across industrial sectors with a focus on different parts of the hemp plant. Under the HAIZ strategy, Global…

Continue Reading

ThursdayFeb 15, 2018 3:10 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Utilizes Oral Digestion Technology to Expand Product Line

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) recently announced its entry into a licensing agreement with Cannfections Group Inc. The agreement offers Lexaria the ability to provide commercial clients with high quality chocolate edibles using its proprietary DehydraTECH™ oral digestion technology. An article discussing the company reads: “Lexaria has developed various products for demonstration, testing and sales, showing wide applicability. These non-psychoactive cannabinoid products have a high-absorption hemp oil formula, are an excellent source of omegas and essential fatty acids and are engineered for physiological performance and recovery. APIs within Lexaria’s products have been shown to reduce anxiety and stress while…

Continue Reading